Type:Tablet
Generic Name:Varenicline Tartrate
Manufacturer:Monicopharma Limited
Price:৳15.00
Smoking cessation aid
Taken after eating with full glass of water
Smoking Cessation Set a date to stop smoking and begin varenicline 1 week before this date Alternatively, the patient can begin varenicline and then quit smoking between days 8 and 35 of treatment Also see Administration Quit smoking date regimen Initiate regimen 1 week before quit smoking date Days 1-3: 0.5 mg PO qDay Days 4-7: 0.5 mg PO BID Day 8 to end of treatment: 1 mg PO BID If quitting is successful after 12 weeks, continue another 12 weeks at 1 mg q12hr Gradual approach to quitting For patients who are sure that they are not able or willing to quit abruptly, consider a gradual approach to quitting smoking with varenicline Begin dosing and reduce smoking by 50% from baseline within the first 4 weeks, by an additional 50% in the next 4 weeks, and continue reducing with the goal of reaching complete abstinence by 12 weeks Continue varenicline for an additional 12 weeks, for a total of 24 weeks of treatment Encourage patients to attempt quitting sooner if they feel ready
<18 years: Safety and efficacy not established
Renal impairment Mild-to-moderate (CrCl ?30 mL/min): No dosage adjustment required Severe (CrCl <30 mL/min): 0.5 mg PO qDay initially; may increase to 0.5 mg PO q12hr ESRD on hemodialysis: Not to exceed 0.5 mg PO qDay
Documented hypersensitivity or skin reactions to drug or components of formulation. Nonsmokers.
Varenicline Tartrate is a partial neuronal alpha 2 beta 2 nicotinic acetylcholine receptor agonist. It works as a smoking cessation aid by preventing nicotine stimulation of mesolimbic dopamine system. It also stimulates dopamine activity but to a much lesser extent than nicotine does, resulting in reduced craving and withdrawal symptoms.
Monitor for signs of suicidal ideation or behaviour, or changes in behaviour. May affect performance of skilled tasks. Not recommended for use in children <18 yr. Pregnancy, lactation.
N>10% Nausea (15-40%; dose related),Abnormal dreams,Headache,Insomnia 1-10% Appetite changes,Chest pain,Constipation,Dry mouth,Dyspepsia,Dyspnea,Flatulence,Gastroesophageal reflux disease (GERD),Fatigue or lethargy,Pruritus,Rash,Somnolence,Rhinorrhea,Vomiting,Upper respiratory tract disorder Frequency Not Defined (selected) Abnormal liver function tests,Anemia,Anxiety,Arrhythmia,Arthralgia,Depression,Diarrhea,Dizziness,Epistaxis,Hypertension,Myocardial infarction (MI),Polyuria,Respiratory disorder
Increased incidence of adverse effects (nausea, vomiting) w/ transdermal nicotine. Increased exposure w/ cimetidine.